Japan Biosimilars Market Size & Outlook, 2020-2027

The biosimilars market in Japan is expected to reach a projected revenue of US$ 1,268.3 million by 2027. A compound annual growth rate of 22% is expected of Japan biosimilars market from 2021 to 2027.
Revenue, 2020 (US$M)
$314.6
Forecast, 2027 (US$M)
$1,268.3
CAGR, 2021 - 2027
22%
Report Coverage
Japan

Japan biosimilars market highlights

  • The Japan biosimilars market generated a revenue of USD 314.6 million in 2020 and is expected to reach USD 1,268.3 million by 2027.
  • The Japan market is expected to grow at a CAGR of 22% from 2021 to 2027.
  • In terms of segment, recombinant non-glycosylated proteins was the largest revenue generating product in 2020.
  • Recombinant Glycosylated Proteins is the most lucrative product segment registering the fastest growth during the forecast period.


Biosimilars market data book summary

Market revenue in 2020USD 314.6 million
Market revenue in 2027USD 1,268.3 million
Growth rate22% (CAGR from 2020 to 2027)
Largest segmentRecombinant non-glycosylated proteins
Fastest growing segmentRecombinant Glycosylated Proteins
Historical data2016 - 2019
Base year2020
Forecast period2021 - 2027
Quantitative unitsRevenue in USD million
Market segmentationRecombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins
Key market players worldwideAmgen Inc, Roche, Sandoz Group AG ADR, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Samsung Bioepis, Biocon, Viatris Inc, Celltrion Healthcare, AbbVie Inc


Other key industry trends

  • In terms of revenue, Japan accounted for 2.4% of the global biosimilars market in 2020.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
  • In Asia Pacific, China biosimilars market is projected to lead the regional market in terms of revenue in 2027.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,725.1 million by 2027.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Biosimilars Market Companies

Name Profile # Employees HQ Website

Japan biosimilars market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biosimilars market will help companies and investors design strategic landscapes.


Recombinant non-glycosylated proteins was the largest segment with a revenue share of 54.61% in 2020. Horizon Databook has segmented the Japan biosimilars market based on recombinant non-glycosylated proteins, recombinant glycosylated proteins covering the revenue growth of each sub-segment from 2016 to 2027.


Reasons to subscribe to Japan biosimilars market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Japan biosimilars market databook

  • Our clientele includes a mix of biosimilars market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Japan biosimilars market , including forecasts for subscribers. This country databook contains high-level insights into Japan biosimilars market from 2016 to 2027, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Japan biosimilars market size, by product, 2016-2027 (US$M)

Japan Biosimilars Market Outlook Share, 2020 & 2027 (US$M)

Japan biosimilars market size, by product, 2016-2027 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more